HIV-1-infection
Conditions
Keywords
HIV, Doravirine, Etravirine
Brief summary
Phase IV, open-label, single arm, unicenter and pilot study on virologically suppressed HIV infected adults with ETR resistance, to assess the efficacy of a Switch strategy from Etravirine (ETR) to Doravirine (DOR).
Interventions
Switch from Etravirine to Doravirine
Sponsors
Fundacion Clinic per a la Recerca Biomédica
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* HIV-1-infected subjects with age ≥18 years old. * Desire of the patient to simplify their ART-regimen. * Having plasma HIV-1 RNA \< 50 copies/mL during at least the previous 24 weeks. * Currently receiving an ETR-containing regimen (unchanged during the previous 24 weeks). * Documented pooled/historical genotype or GRT in pro-viral DNA must show the presence of 103N and/or 181C and/or 190A and/or 100I and/or 138K/A.
Exclusion criteria
* Documented pooled/historical genotype or GRT in pro-viral DNA of any DOR-DRM (Mutations V106A, Y188L, and M230L, and combinations of V106A and L234I; V106A and F227L and L234I; and V106A and 190A and F227L). * Pregnant, breastfeeding women, women with a positive pregnancy test at the time of screening, sexually active fertile women wishing to conceive or unwilling to commit to contraceptive methods, for the duration of the study and until 4 weeks after the last dose of study medication. All women are considered fertile unless they have undergone a sterilizing surgery or are over the age of 50 with spontaneous amenorrhea for over 12 months prior to study entry. * Active tuberculosis infection. * Any clinical condition or therapy that, in the opinion of the Investigator, would make the individual unsuitable for the study or unable to comply with the dosing requirements.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of participants with confirmed HIV viral load>50 copies/mL | at week 24 | Measured by blood HIV viral load |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of participants with HIV viral load<50 copies/mL | at week 12, 24 and 48 | Measured by blood HIV viral load |
| Changes in CD4, CD8 cell counts and ratio CD4/CD8 | at 48 weeks | Measured by blood CD4, CD8 and CD/4/CD8 ratio |
| Incidence of Treatment-Emergent adverse events and serious adverse events | at week 48 | Measured by numer of AEs and SAEs related to the treatment |
| Percentage of participants with HIV viral load>50 copies/mL | at week 12 and 48 | Measured by blood HIV viral load |
| Maximum concentrations (Cmax) of DRV/r and DRV/c with DOR | at weeks 2 and 4 | — |
| Concentrations at the end of the dosing interval (C24) of DRV/r and DRV/c with DOR | at weeks 2 and 4 | — |
| Elimination half-life (t1/2) of DRV/r and DRV/c with DOR | at weeks 2 and 4 | — |
| AUC during the dose interval (AUC0-24) of DRV/r and DRV/c with DOR | at weeks 2 and 4 | — |
Countries
Spain
Outcome results
None listed